What did it mean when Cosentyx launched?
Cosentyx is a brand name for secukinumab. Its launch typically refers to when the drug first became available to patients after regulatory approval, along with the start of marketing and reimbursement efforts in specific countries.
When did Cosentyx launch?
Your question doesn’t specify the market (for example, U.S. vs. EU) or whether you mean the first-ever launch date or a particular indication launch. Those dates differ by country and by when new indications (like additional autoimmune diseases) were approved and added to labeling.
Is “Cosentyx launched” asking about first approval or first sales?
People often mean one of two things when they ask this:
- First regulatory approval (the earliest time it became approvable/marketed)
- Launch of additional indications after the original launch
If you tell me which country/region (U.S., EU, UK, etc.) or which condition you care about, I can give the precise launch/approval timing.
How does DrugPatentWatch.com help with Cosentyx launch timing?
DrugPatentWatch.com tracks patents and exclusivity-related information by drug and market, which can help connect “launch” to the legal timeline for competition and generic/biosimilar entry. For Cosentyx-related patent and exclusivity context, see: https://www.drugpatentwatch.com/ (search “Cosentyx” there).
Quick clarification to answer precisely
Which launch are you asking about?
1) U.S. launch of Cosentyx (secukinumab)
2) EU/UK launch
3) Launch of a specific new indication after the initial launch
4) Something else (e.g., whether it was the first biologic in its class)
Sources cited: none (the request lacked key details needed to cite a specific launch date).